In October 2022, these guidelines were reviewed by an expert work group convened by
ASH. Review included limited searches for new evidence and discussion of the search …

Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer -
Kahale, LA - 2018 | Cochrane Library Skip to Content Cookies Our site uses cookies to improve …

Background Venous thromboembolism (VTE) represents a leading cause of morbidity and
mortality among patients with cancer. Methods Hospitalization data reported on adult cancer …

Background Central venous catheter (CVC) placement increases the risk of thrombosis in
people with cancer. Thrombosis often necessitates the removal of the CVC, resulting in …

Cancer-associated venous thromboembolism (VTE) has major consequences for patients,
including morbidity and risk of mortality. However, there is substantial variation in risk …

Ulcerative colitis (UC) is a chronic inflammatory bowel disease of the colorectum which
results from a complex interplay between environmental, genetic and microbial factors. One …

Background Compared with people without cancer, people with cancer who receive
anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop …

Background The choice of the appropriate perioperative thromboprophylaxis for people with
cancer depends on the relative benefits and harms of different anticoagulants. Objectives To …

Essentials• The Khorana score is validated for risk of venous thromboembolism (VTE) in
cancer outpatients.• We conducted a multicenter analysis of medically hospitalized cancer …

Venous thromboembolism (VTE) occurring in hospitalized medical patients is associated
with increased length of hospitalization, high rate of acute care hospital transfer, longer …